Understanding bone death
Researchers discover new genetic mutation linked to osteonecrosis of the hip
Scientists at the Research Institute of 麻豆AV Health Centre (RI-MUHC) have discovered a new genetic mutation linked to osteonecrosis of the hip, specifically the femoral head 鈥� the spherical-shaped mass at the top of the femur. This breakthrough could allow doctors to identify and treat the disease before symptoms arise and potentially avoid hip replacements.
Osteonecrosis or 鈥渂one death鈥� of the femoral head is a serious disease that is caused by interruption of blood flow in the hip bone. Patients experience pain as the disease progresses and the bone and surrounding joint collapse. Ultimately, in end-stage osteoarthritis, the patient becomes unable to walk and the hip joint must be replaced. 鈥淚t is a severely debilitating disease that is usually linked to identifiable risk factors such as glucocorticoid treatments, blood cancers and in some rare cases, to a genetic cause,鈥� explains Dr. Chantal S茅guin, Hematologist-oncologist at the Bone Engineering and Vascular Biology Research Lab of the RI-MUHC, and senior author on the scientific paper published recently in the Journal of Medical Genetics.
Through the specialized Osteonecrosis Clinic established at the MUHC鈥檚 Montreal General Hospital, led by Dr. S茅guin and orthopedic surgeon Dr. Ed Harvey, the researchers diagnosed advanced osteonecrosis in 4 out of 6 siblings in a family of European descent. Their team discovered a novel genetic mutation on a gene called TRPV4 (transient receptor potential vanilloid 4). The TRPV4 gene is known to play a critical role in blood flow control and bone cell development. Until this new discovery, only one other mutation had been identified in a few families of Asian descent and the findings have had limited potential for early diagnosis and new targeted therapy.
鈥淭he mutation was found to be common to all affected family members and absent in the unaffected family member, linking this new mutation to osteonecrosis,鈥� says Dr. S茅guin. 鈥淲hile it was known that pathogenic TRPV4 mutations affected the skeleton and the nervous system, this is the first time it has been associated with osteonecrosis of the femoral head.鈥�
Osteonecrosis can affect the young
Although the true prevalence of the disease is unknown, as many as 30,000 new patients are diagnosed each year in the United States, and the incidence is increasing. Many patients are under the age of 25 when diagnosed. The lack of knowledge surrounding osteonecrosis places a major financial burden on the Quebec and Canadian healthcare system.
"If we consider all Europeans and their distribution worldwide, it is likely that this mutation could be found in larger populations,鈥� explains Dr. S茅guin. 鈥淭he identification of this novel mutation will help to reveal the biological pathways that lead to the disease, and aid in the development of new treatments that target its cause rather than its symptoms."
This novel discovery could also help to better understand the biological mechanisms in the much more common form of osteonecrosis of the femoral head, namely osteonecrosis induced by the use of glucocorticoids, or more commonly, steroids. Glucocorticoids are a family of medications used worldwide as either an anti-inflammatory agent, or as an important drug in many chemotherapy regimens used to treat patients with blood cancer. It is also well known that people who are using steroid medication for various illnesses are also at risk and it is estimated that greater than 60 million people are presently taking this medication worldwide.
Funding
This research was funded by Fonds de Recherche Qu茅bec - Sant茅 (FRQ-S), Montreal General Hospital Foundation, Yvon Boulanger Foundation, Canadian Institutes of Health Research, National Institutes of Health, Fondation Leducq and Totman Medical Research Trust.
About the research
The study was co-authored by Wayne Mah,1 Swapnil K. Sonkusare,2,3,4 Tracy Wang,1 Bouziane Azeddine,1 Mihaela Pupavac,5 Jian Carrot-Zhang,5,6 Jacek Majewski,5,6 Edward J. Harvey,7 Laura Russell,5 Colin Chalk,8 David S. Rosenblatt,5 Mark T. Nelson,2,9 Chantal S茅guin1
1 Department of Medicine, Division of Hematology and Oncology, 麻豆AV Health Centre, Montreal, Quebec, Canada, 2 Department of Pharmacology, University of Vermont, Burlington, Vermont, USA,3 Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, Virginia, USA, 4 Robert M. Berne Cardiovascular Research Center, University of Virginia, Charlottesville, Virginia, USA, 5 Department of Human Genetics, 麻豆AV, Montreal, Quebec, Canada, 6 麻豆AV and Genome Qu茅bec Innovation Centre, Montreal, Quebec, Canada, 7 Department of Surgery, Division of Orthopedic Surgery, 麻豆AV Health Centre, Montreal, Quebec, Canada, 8Department of Neurology & Neurosurgery, 麻豆AV, Montreal, Quebec, Canada,9 Institute of Cardiovascular Sciences, University of Manchester, Manchester, UK.
